683 Capital Management’s Strongbridge Biopharma plc. SBBP Stock Holding History

683 Capital Management’s Portfolio SBBP Stock Details SBBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,595,082	Closed	-$3.88M	–	273
2020 Q4	$3.88M	Hold	1,595,082	–	–	0.18%	80
2020 Q3	$3.35M	Buy	1,595,082 +1,136,111	+248%	+$3.83M	0.25%	68
2020 Q2	$1.74M	Hold	458,971	–	–	0.14%	85
2020 Q1	$868K	Sell	458,971 -150,000	-25%	-$390K	0.1%	93
2019 Q4	$1.27M	Sell	608,971 -314,729	-34%	-$603K	0.15%	65
2019 Q3	$2.21M	Hold	923,700	–	–	0.25%	61
2019 Q2	$2.89M	Buy	923,700 +75,000	+9%	+$275K	0.26%	72
2019 Q1	$4.23M	Hold	848,700	–	–	0.38%	54
2018 Q4	$3.8M	Buy	848,700 +549,000	+183%	+$2.68M	0.23%	71
2018 Q3	$1.45M	Buy	299,700 +49,700	+20%	+$254K	0.09%	92
2018 Q2	$1.5M	Hold	250,000	–	–	0.1%	91
2018 Q1	$2.21M	Buy	250,000 +50,000	+25%	+$374K	0.2%	77
2017 Q4	$1.45M	Buy	+200,000	New	+$1.25M	0.12%	100

Other funds holding SBBP

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

683 Capital Management's SBBP Position: Q1 2021 in Review

683 Capital Management sold out of Strongbridge Biopharma plc. (SBBP) in Q1 2021, closing a stake of 1,595,082 shares — an estimated $3.88M sold.

683 Capital Management first reported a position in SBBP in Q4 2017 and held it in 13 quarters. The position peaked at $4.23M in Q1 2019. 74 funds tracked by Wall St. Rank hold SBBP as of Q1 2021.

683 Capital Management reported no remaining Strongbridge Biopharma plc. position as of Q1 2021 after selling out during the quarter.
683 Capital Management sold 1,595,082 Strongbridge Biopharma plc. shares in Q1 2021, an estimated $3.88M.
683 Capital Management first reported a position in Strongbridge Biopharma plc. in Q4 2017 and held it in 13 quarters.
683 Capital Management's Strongbridge Biopharma plc. position peaked at $4.23M in Q1 2019.
74 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q1 2021.

Based on 683 Capital Management's 13F filing for Q1 2021, filed 17 May 2021.